Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Mana.bio›
Analysis
Mana.bio

Mana.bio

Seed

Mana.bio: An AI-driven startup specializing in LNP development for mRNA-based therapies and vaccines.

HQ
Tel Aviv, Tel Aviv District, IL
Founded
2021
Loading
Overview
Analysis
Compare
Fundraising
Employees
News

Contents

  1. 01Executive Summary
  2. 02Market Outlook
  3. 03Competitive Strengths
  1. 01Executive Summary
  2. 02Market Outlook
  3. 03Competitive Strengths

Memo

Mana.bio is an early-stage biotechnology company based in Tel Aviv, Israel, with a San Francisco presence. Its founders combine software entrepreneurship with deep expertise in nanomedicine and artificial intelligence.

The company's platform and Mina AI agent are positioned in the competitive LNP delivery space alongside Recode Therapeutics, Acuitas Therapeutics and other LNP technology providers. Key near-term milestones include expanding partnerships, advancing lead programs, and presenting additional preclinical data at scientific conferences.

Market Outlook

The market for nucleic acid therapeutics and vaccines is expanding as mRNA, gene therapy and gene editing modalities mature. A major bottleneck is safe and effective delivery to tissues beyond the liver, creating demand for next-generation lipid nanoparticle platforms.

Mana.bio targets this opportunity with AI-enabled LNP discovery for extrahepatic delivery. If its predictive models and preclinical data translate to the clinic, the company could become a platform partner for biopharma developers of RNA medicines and genetic therapies.

Competitive Advantages

Mana.bio's core advantage is the integration of machine learning with high-throughput LNP synthesis and screening, producing a closed-loop design-build-test-learn cycle. The platform is trained on a large curated LNP dataset and aims to predict safety, tropism and physicochemical properties.

This enables tissue-specific delivery beyond the liver, a key bottleneck for nucleic acid therapeutics. The company also offers Mina, a publicly available LLM-based AI agent for lipid nanoparticles that lowers the barrier for researchers to explore formulation insights.